You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameXylometazoline
Accession NumberDB06694
TypeSmall Molecule
GroupsApproved
DescriptionA nasal vasoconstricting decongestant drug which acts by binding to the same receptors as adrenaline. It is applied as a spray or as drops into the nose to ease inflammation and congestion of the nasal passageways. It binds alpha-adrenergic receptors to activate the adrenal system which causes systemic vasoconstriction, thereby easing nasal congestion.
Structure
Thumb
Synonyms
Balminil
Xylomethazoline
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Way Moisturizing Reliefspray.01 L/LnasalNovartis Consumer Health, Inc.2010-01-01Not applicableUs
Aqua Maris Fast Acting Decongestantspray10 mg/10mLnasalJgl North America Llc2012-12-15Not applicableUs
Aqua Maris Kids Fast Acting Decongestantspray.05 mg/10mLnasalJgl North America Llc2010-09-27Not applicableUs
Balminil Decongestsolution0.1 %nasalTeva Canada Limited2007-12-14Not applicableCanada
Balminil Nasal Decongestantspray0.1 %nasalTeva Canada Limited1997-08-26Not applicableCanada
Certified Decongestant Nasal Spray .1%solution; spray0.1 %nasalProdemdis Enr.1996-09-192010-07-15Canada
Cold and Allergy Decongestant Nasal Sprayspray0.1 %nasalTeva Canada Limited2011-10-01Not applicableCanada
Decongest Nasalsolution0.1 %nasalTeva Canada Limited2007-12-20Not applicableCanada
Decongestant Nasal Sprayspray0.1 %nasalJamp Pharma Corporation2005-01-31Not applicableCanada
Decongestant Nasal Sprayspray0.1 %nasalPharmascience Inc2003-02-01Not applicableCanada
Decongestant Nasal Sprayspray0.1 %nasalCrlsNot applicableNot applicableCanada
Decongestant Nasal Spray - 0.10%liquid; spray.1 %nasalWes Pak Products Ltd.1998-01-142000-08-04Canada
Decongestant Nasal Spray 0.1%solution; spray.1 %nasalProdemdis Enr.1996-09-192008-08-08Canada
Decongestant Nasal Spray 0.1%spray.1 %nasalTeva Canada Limited1993-12-31Not applicableCanada
Decongestant Nasal Spray 0.1% USPspray.1 %nasalKsl Pharmaceuticals1992-12-311996-09-09Canada
Decongestant Nasal Spray 0.1% W/Vspray.1 %nasalStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Decongestant Nasal Spray With Moisturizersspray0.1 %nasalJamp Pharma Corporation2005-01-31Not applicableCanada
Decongestant Nasal Spray With Moisturizersspray0.1 %nasalPharmascience Inc2003-02-01Not applicableCanada
Decongestant Nose Drops 0.1%drops0.1 %nasalLaboratoires Confab Inc1991-12-31Not applicableCanada
Nasal Decongestant Spray With Moisturizersliquid0.1 %nasalLaboratoires Confab Inc2000-11-11Not applicableCanada
Nasal Decongestant Spray With Moisturizersspray0.1 %nasalCrlsNot applicableNot applicableCanada
Otrivin Allergy and Cold Decongestant Nasal Sprayspray0.05 %nasalGlaxosmithkline Consumer Healthcare Inc.1999-08-09Not applicableCanada
Otrivin Cold and Allergy Decongestant Nose Dropssolution0.1 %nasalGlaxosmithkline Consumer Healthcare Inc.1960-12-31Not applicableCanada
Otrivin Cold and Allergy Relief With Moisturizersspray0.1 %nasalGlaxosmithkline Consumer Healthcare Inc.1996-10-15Not applicableCanada
Otrivin Decongestant Nose Drops 0.05%drops0.05 %nasalNovartis Consumer Health Canada Inc.1999-11-122007-03-23Canada
Otrivin Medicated Cold & Allergy Reliefspray0.1 %nasalGlaxosmithkline Consumer Healthcare Inc.1961-12-31Not applicableCanada
Otrivin Medicated Complete Nasal Carespray0.1 %nasalGlaxosmithkline Consumer Healthcare Inc.2010-08-02Not applicableCanada
Otrivin Menthol - Asp-liq 0.1%liquid; spray.1 %nasalNovartis Consumer Health Canada Inc.1994-12-312009-06-29Canada
Otrivin Pediatric Decongestant Nose Dropsdrops.05 %nasalNovartis Consumer Health Canada Inc.1960-12-312000-01-18Canada
Otrivin Pediatric Nasal Spray 0.05%spray.05 %nasalNovartis Consumer Health Canada Inc.1985-12-311999-07-21Canada
Otrivin Sinus Reliefsolution0.1 %nasalGlaxosmithkline Consumer Healthcare Inc.Not applicableNot applicableCanada
Otrivin With M-D Pumpspray.1 %nasalNovartis Consumer Health Canada Inc.1987-12-312009-06-29Canada
Sinosil Nasal Decongestantspray.015 mL/15mLnasalHerbion Pakistan Pvt Ltd2011-02-09Not applicableUs
Vaporisateur Nasal Decongestionnantsolution0.1 %nasalLaboratoires Confab Inc1991-12-31Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
OtrivenNot Available
OtrivinNot Available
OtrivineNot Available
OtrixNot Available
XylometNot Available
XylostarIntas
Brand mixtures
NameLabellerIngredients
Ophtrivin A Ophthalmic DpsCiba Vision Canada Inc
Salts
Name/CASStructureProperties
Xylometazoline hydrochloride
ThumbNot applicableDBSALT001557
Categories
UNIIWPY40FTH8K
CAS number526-36-3
WeightAverage: 244.3752
Monoisotopic: 244.193948778
Chemical FormulaC16H24N2
InChI KeyInChIKey=HUCJFAOMUPXHDK-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
IUPAC Name
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
SMILES
CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropanes
Direct ParentPhenylpropanes
Alternative Parents
Substituents
  • Phenylpropane
  • Imidolactam
  • 2-imidazoline
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIt is used for treating nasal congestion and minor inflammation due to allergies or colds.
PharmacodynamicsXylometazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion. The sympathomimetic action of xylometazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (8-12 hours) decongesting effect.
Mechanism of actionXylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier+0.7293
Caco-2 permeable-0.5133
P-glycoprotein substrateSubstrate0.8254
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IINon-inhibitor0.8244
Renal organic cation transporterInhibitor0.6924
CYP450 2C9 substrateNon-substrate0.7815
CYP450 2D6 substrateNon-substrate0.531
CYP450 3A4 substrateNon-substrate0.5755
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9031
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9147
Ames testNon AMES toxic0.8306
CarcinogenicityNon-carcinogens0.9124
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1884 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9218
hERG inhibition (predictor II)Non-inhibitor0.745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Spraynasal.01 L/L
Spraynasal10 mg/10mL
Spraynasal.05 mg/10mL
Spraynasal0.1 %
Solution; spraynasal0.1 %
Solution; spraynasal.1 %
Spraynasal.1 %
Dropsnasal0.1 %
Liquidnasal0.1 %
Dropsophthalmic
Spraynasal0.05 %
Dropsnasal0.05 %
Liquid; spraynasal.1 %
Dropsnasal.05 %
Spraynasal.05 %
Spraynasal.015 mL/15mL
Solutionnasal0.1 %
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point132 °CPhysProp
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00893 mg/mLALOGPS
logP4.68ALOGPS
logP3.78ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)10.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity77.82 m3·mol-1ChemAxon
Polarizability29.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
External Links
ATC CodesS01GA53R01AB06R01AA07S01GA03
AHFS Codes
  • 52:32.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Xylometazoline.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Xylometazoline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Xylometazoline.
AcebutololAcebutolol may increase the hypotensive activities of Xylometazoline.
AlfuzosinAlfuzosin may increase the hypotensive activities of Xylometazoline.
AliskirenXylometazoline may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Xylometazoline.
AmbrisentanXylometazoline may increase the hypotensive activities of Ambrisentan.
AmifostineXylometazoline may increase the hypotensive activities of Amifostine.
AmineptineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Amineptine.
AmitriptylineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Xylometazoline.
AmobarbitalThe metabolism of Xylometazoline can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Xylometazoline.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Xylometazoline.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Xylometazoline.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Xylometazoline.
ArotinololXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Xylometazoline.
AtenololAtenolol may increase the hypotensive activities of Xylometazoline.
AtosibanThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Atosiban.
Atracurium besylateXylometazoline may increase the neuromuscular blocking activities of Atracurium besylate.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Xylometazoline.
BarbitalThe metabolism of Xylometazoline can be increased when combined with Barbital.
BefunololXylometazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBenazepril may increase the hypotensive activities of Xylometazoline.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Xylometazoline.
BenmoxinBenmoxin may increase the hypotensive activities of Xylometazoline.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Xylometazoline.
BepridilBepridil may increase the hypotensive activities of Xylometazoline.
BetaxololBetaxolol may increase the hypotensive activities of Xylometazoline.
BethanidineBethanidine may increase the hypotensive activities of Xylometazoline.
BevantololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Xylometazoline.
BimatoprostBimatoprost may increase the hypotensive activities of Xylometazoline.
BisoprololBisoprolol may increase the hypotensive activities of Xylometazoline.
BopindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BosentanBosentan may increase the hypotensive activities of Xylometazoline.
BretyliumBretylium may increase the hypotensive activities of Xylometazoline.
BrimonidineXylometazoline may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Xylometazoline.
BufuralolXylometazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupranololXylometazoline may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Xylometazoline.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Xylometazoline.
CandesartanCandesartan may increase the hypotensive activities of Xylometazoline.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Xylometazoline.
CandoxatrilCandoxatril may increase the hypotensive activities of Xylometazoline.
CaptoprilCaptopril may increase the hypotensive activities of Xylometazoline.
CaroxazoneCaroxazone may increase the hypotensive activities of Xylometazoline.
CarteololCarteolol may increase the hypotensive activities of Xylometazoline.
CarvedilolCarvedilol may increase the hypotensive activities of Xylometazoline.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Xylometazoline.
CeliprololCeliprolol may increase the hypotensive activities of Xylometazoline.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Xylometazoline.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Xylometazoline.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Xylometazoline.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Xylometazoline.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Xylometazoline.
CilazaprilCilazapril may increase the hypotensive activities of Xylometazoline.
CimetidineThe serum concentration of Xylometazoline can be increased when it is combined with Cimetidine.
ClomipramineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Xylometazoline.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline.
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Xylometazoline.
CryptenamineCryptenamine may increase the hypotensive activities of Xylometazoline.
CyclobenzaprineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Cyclobenzaprine.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.
CyclothiazideCyclothiazide may increase the hypotensive activities of Xylometazoline.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Xylometazoline.
DebrisoquinDebrisoquin may increase the hypotensive activities of Xylometazoline.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Xylometazoline.
DeserpidineXylometazoline may increase the hypotensive activities of Deserpidine.
DesipramineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Desipramine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Xylometazoline.
DiazoxideDiazoxide may increase the hypotensive activities of Xylometazoline.
DiltiazemDiltiazem may increase the hypotensive activities of Xylometazoline.
DorzolamideDorzolamide may increase the hypotensive activities of Xylometazoline.
DosulepinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Dosulepin.
DoxazosinDoxazosin may increase the hypotensive activities of Xylometazoline.
DoxepinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Doxepin.
DuloxetineDuloxetine may decrease the antihypertensive activities of Xylometazoline.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Xylometazoline.
EfavirenzThe serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Xylometazoline.
EfonidipineXylometazoline may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Xylometazoline.
EnalaprilatXylometazoline may increase the hypotensive activities of Enalaprilat.
EpoprostenolEpoprostenol may increase the hypotensive activities of Xylometazoline.
EprosartanEprosartan may increase the hypotensive activities of Xylometazoline.
EsmirtazapineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Esmirtazapine.
EsmololXylometazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.
FelodipineFelodipine may increase the hypotensive activities of Xylometazoline.
FenoldopamFenoldopam may increase the hypotensive activities of Xylometazoline.
FluconazoleThe serum concentration of Xylometazoline can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Xylometazoline.
FosinoprilFosinopril may increase the hypotensive activities of Xylometazoline.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Xylometazoline.
FurazolidoneFurazolidone may increase the hypotensive activities of Xylometazoline.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Xylometazoline.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Xylometazoline.
GuanabenzGuanabenz may increase the hypotensive activities of Xylometazoline.
GuanadrelGuanadrel may increase the hypotensive activities of Xylometazoline.
GuanethidineGuanethidine may increase the hypotensive activities of Xylometazoline.
GuanfacineGuanfacine may increase the hypotensive activities of Xylometazoline.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Xylometazoline.
HexamethoniumXylometazoline may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Xylometazoline.
HexobarbitalThe metabolism of Xylometazoline can be increased when combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Xylometazoline.
HydralazineHydralazine may increase the hypotensive activities of Xylometazoline.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Xylometazoline.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Xylometazoline.
IloprostIloprost may increase the hypotensive activities of Xylometazoline.
ImipramineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Imipramine.
IndapamideIndapamide may increase the hypotensive activities of Xylometazoline.
IndenololXylometazoline may increase the hypotensive activities of Indenolol.
IndoraminXylometazoline may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Xylometazoline.
IproniazidIproniazid may increase the hypotensive activities of Xylometazoline.
IrbesartanIrbesartan may increase the hypotensive activities of Xylometazoline.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Xylometazoline.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Xylometazoline.
IsradipineIsradipine may increase the hypotensive activities of Xylometazoline.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Xylometazoline.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Xylometazoline.
LabetalolLabetalol may increase the hypotensive activities of Xylometazoline.
LacidipineXylometazoline may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Xylometazoline.
LercanidipineLercanidipine may increase the hypotensive activities of Xylometazoline.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Xylometazoline.
LisinoprilLisinopril may increase the hypotensive activities of Xylometazoline.
LofexidineLofexidine may increase the hypotensive activities of Xylometazoline.
LosartanLosartan may increase the hypotensive activities of Xylometazoline.
MacitentanXylometazoline may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Sulfate.
ManidipineXylometazoline may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Xylometazoline.
MecamylamineMecamylamine may increase the hypotensive activities of Xylometazoline.
MethohexitalThe metabolism of Xylometazoline can be increased when combined with Methohexital.
MethyldopaMethyldopa may increase the hypotensive activities of Xylometazoline.
Methylene blueMethylene blue may increase the hypotensive activities of Xylometazoline.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Xylometazoline.
MethylphenobarbitalThe metabolism of Xylometazoline can be increased when combined with Methylphenobarbital.
MetipranololMetipranolol may increase the hypotensive activities of Xylometazoline.
MetolazoneMetolazone may increase the hypotensive activities of Xylometazoline.
MetoprololMetoprolol may increase the hypotensive activities of Xylometazoline.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Xylometazoline.
MianserinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mianserin.
MibefradilMibefradil may increase the hypotensive activities of Xylometazoline.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Xylometazoline.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Xylometazoline.
MilnacipranMilnacipran may decrease the antihypertensive activities of Xylometazoline.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Xylometazoline.
MinaprineMinaprine may increase the hypotensive activities of Xylometazoline.
MinoxidilMinoxidil may increase the hypotensive activities of Xylometazoline.
MirtazapineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mirtazapine.
MivacuriumXylometazoline may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Xylometazoline.
MoexiprilMoexipril may increase the hypotensive activities of Xylometazoline.
MolsidomineMolsidomine may increase the hypotensive activities of Xylometazoline.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Xylometazoline.
MoxonidineXylometazoline may increase the hypotensive activities of Moxonidine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Xylometazoline.
NadololNadolol may increase the hypotensive activities of Xylometazoline.
NafcillinThe metabolism of Xylometazoline can be increased when combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Xylometazoline.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Xylometazoline.
NebivololNebivolol may increase the hypotensive activities of Xylometazoline.
NialamideNialamide may increase the hypotensive activities of Xylometazoline.
NicardipineNicardipine may increase the hypotensive activities of Xylometazoline.
NicorandilXylometazoline may increase the hypotensive activities of Nicorandil.
NiguldipineXylometazoline may increase the hypotensive activities of Niguldipine.
NilvadipineXylometazoline may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Xylometazoline.
NisoldipineNisoldipine may increase the hypotensive activities of Xylometazoline.
NitrendipineNitrendipine may increase the hypotensive activities of Xylometazoline.
NitroprussideXylometazoline may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Xylometazoline.
NortriptylineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Nortriptyline.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Xylometazoline.
ObinutuzumabXylometazoline may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Xylometazoline.
OlmesartanOlmesartan may increase the hypotensive activities of Xylometazoline.
OmapatrilatOmapatrilat may increase the hypotensive activities of Xylometazoline.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Xylometazoline.
OxprenololOxprenolol may increase the hypotensive activities of Xylometazoline.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Xylometazoline.
PargylinePargyline may increase the hypotensive activities of Xylometazoline.
PenbutololPenbutolol may increase the hypotensive activities of Xylometazoline.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Xylometazoline.
PentobarbitalThe metabolism of Xylometazoline can be increased when combined with Pentobarbital.
PentoliniumPentolinium may increase the hypotensive activities of Xylometazoline.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Xylometazoline.
PerindoprilPerindopril may increase the hypotensive activities of Xylometazoline.
PhenelzinePhenelzine may increase the hypotensive activities of Xylometazoline.
PheniprazinePheniprazine may increase the hypotensive activities of Xylometazoline.
PhenobarbitalThe metabolism of Xylometazoline can be increased when combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Xylometazoline.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Xylometazoline.
PhentolaminePhentolamine may increase the hypotensive activities of Xylometazoline.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Xylometazoline.
PinacidilXylometazoline may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Xylometazoline.
PirlindolePirlindole may increase the hypotensive activities of Xylometazoline.
PivhydrazinePivhydrazine may increase the hypotensive activities of Xylometazoline.
PolythiazidePolythiazide may increase the hypotensive activities of Xylometazoline.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Xylometazoline.
PractololXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.
PrazosinPrazosin may increase the hypotensive activities of Xylometazoline.
PrimidoneThe metabolism of Xylometazoline can be increased when combined with Primidone.
PropranololPropranolol may increase the hypotensive activities of Xylometazoline.
ProtriptylineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Protriptyline.
QuinaprilQuinapril may increase the hypotensive activities of Xylometazoline.
QuinineQuinine may increase the hypotensive activities of Xylometazoline.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Xylometazoline.
RamiprilRamipril may increase the hypotensive activities of Xylometazoline.
RapacuroniumXylometazoline may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Xylometazoline.
RemikirenRemikiren may increase the hypotensive activities of Xylometazoline.
RescinnamineXylometazoline may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Xylometazoline.
RiociguatXylometazoline may increase the hypotensive activities of Riociguat.
RituximabXylometazoline may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Xylometazoline.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Xylometazoline.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Xylometazoline.
SaprisartanSaprisartan may increase the hypotensive activities of Xylometazoline.
SecobarbitalThe metabolism of Xylometazoline can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Xylometazoline.
SelexipagXylometazoline may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Xylometazoline.
SildenafilSildenafil may increase the antihypertensive activities of Xylometazoline.
SilodosinSilodosin may increase the hypotensive activities of Xylometazoline.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Xylometazoline.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Xylometazoline.
SitaxentanXylometazoline may increase the hypotensive activities of Sitaxentan.
SotalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.
SpiraprilSpirapril may increase the hypotensive activities of Xylometazoline.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Xylometazoline.
TadalafilTadalafil may increase the antihypertensive activities of Xylometazoline.
TamsulosinTamsulosin may increase the hypotensive activities of Xylometazoline.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Xylometazoline.
TelmisartanTelmisartan may increase the hypotensive activities of Xylometazoline.
TemocaprilXylometazoline may increase the hypotensive activities of Temocapril.
TerazosinTerazosin may increase the hypotensive activities of Xylometazoline.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Xylometazoline.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Xylometazoline.
TerlipressinTerlipressin may increase the hypotensive activities of Xylometazoline.
ThiamylalThe metabolism of Xylometazoline can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Xylometazoline can be increased when combined with Thiopental.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Xylometazoline.
TianeptineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Tianeptine.
TiboloneXylometazoline may increase the hypotensive activities of Tibolone.
TicrynafenTicrynafen may increase the hypotensive activities of Xylometazoline.
TimololTimolol may increase the hypotensive activities of Xylometazoline.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Xylometazoline.
TolazolineTolazoline may increase the hypotensive activities of Xylometazoline.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Xylometazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Xylometazoline.
TorasemideTorasemide may increase the hypotensive activities of Xylometazoline.
TrandolaprilTrandolapril may increase the hypotensive activities of Xylometazoline.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Xylometazoline.
TranylcypromineTranylcypromine may increase the hypotensive activities of Xylometazoline.
TravoprostTravoprost may increase the hypotensive activities of Xylometazoline.
TreprostinilTreprostinil may increase the hypotensive activities of Xylometazoline.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Xylometazoline.
TrimazosinXylometazoline may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Xylometazoline.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Xylometazoline.
TrimipramineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Trimipramine.
UdenafilUdenafil may increase the antihypertensive activities of Xylometazoline.
UnoprostoneXylometazoline may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Xylometazoline.
VardenafilVardenafil may increase the antihypertensive activities of Xylometazoline.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Xylometazoline.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Xylometazoline.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610 ]
  2. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
  2. Petrusewicz J, Kaliszan R: Effect of imidazoline drugs on human blood platelet aggregation. Thromb Haemost. 1985 Dec 17;54(4):784-7. [PubMed:2868542 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Comments
comments powered by Disqus
Drug created on April 25, 2010 17:54 / Updated on August 17, 2016 12:24